CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...4950515253545556575859...39323933»
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Neulasta (pegfilgrastim) / Roche
    Journal, Combination therapy:  The Utility of Primary Prophylaxis with Pegfilgrastim in Combination with Polatuzumab Vedotin Therapy (Pubmed Central) -  Aug 27, 2024   
    The duration of hospitalization significantly decreased in the Pola-BR group with G-CSF(11 days vs. 18 days in the group without G-CSF), suggesting that prophylaxis might contribute to this reduction. Although not statistically significant, prophylactic G-CSF administration tended to reduce the incidence of Grade 3 or higher leukopenia and neutropenia, suggesting that primary prophylactic G-CSF administration in Pola combination therapy could contribute to reduced hematologic toxicity.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Retrospective data, Journal, Metastases:  Evaluation of Serum KL-6 Levels in Metastatic Gastric Cancer Patients without Interstitial Lung Disease (Pubmed Central) -  Aug 27, 2024   
    Therefore, we retrospectively reviewed the medical records of patients with gastric cancer and serum KL-6 levels measured prior to nivolumab-containing therapies...Moreover, we conducted a representative case presentation. Due to the increasing immune checkpoint inhibitor use in gastric cancer management, awareness concerning potentially increased serum KL-6 levels in patients with gastric cancer without ILD would be useful for physicians due to the more frequent opportunities to measure serum KL-6 levels for early detection and differential diagnosis of ILD.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Journal:  Antibody-Drug Conjugates against Urothelial Carcinoma-Current Issues and Future Development (Pubmed Central) -  Aug 27, 2024   
    Recently, several reports demonstarated the efficacy and safety of enfortumab vedotin in real-world clinical practice, highlighting its current status and challenges. In addition, the combination of enfortumab vedotin and pembrolizumab for the treatment of untreated unresectable or metastatic urothelial carcinoma has received expedited approval by the FDA and is expected to become a key drug in urothelial carcinoma.
  • ||||||||||  Journal:  Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development (Pubmed Central) -  Aug 27, 2024   
    In DLBCL patients with an international prognostic index score(IPI score)of 2 or higher, the combination of PV plus rituximab, cyclophosphamide, doxorubicin, and prednisone(PV+R-CHP)extended PFS at 2 years compared with R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), which has long been the standard of care. As shown, ADCs exhibit high therapeutic efficacy in leukemia and lymphoma treatment, but many aspects of their resistance mechanisms remain unclear and require further research.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Clinical data, Journal, Checkpoint inhibition:  Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. (Pubmed Central) -  Aug 27, 2024   
    However, rigorous validation studies across diverse pharmacist queries, drug classes and populations, and engineering to secure patient privacy will be needed to enhance LLM utility. Late immunotherapy infusion times were associated with inferior outcomes when considering all infusions, but not when considering initial (first 4) infusions.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. (Pubmed Central) -  Aug 27, 2024   
    P2
    Multiomic analyses showed that CD8-low responders had an inflammatory tumor microenvironment pretreatment, enhanced by an influx of CD8 T cells, CD4 T cells, B cells, and macrophages upon treatment. These findings reveal crucial pan-cancer immunological features for ICI response in patients with metastatic disease.
  • ||||||||||  Rituxan (rituximab) / Roche
    Review, Journal:  The 2023 revised diagnostic criteria for IgG4-related ophthalmic disease. (Pubmed Central) -  Aug 27, 2024   
    We reviewed published case reports of optic neuropathy in IgG4-related disease (n?=?44), and in many cases, decreased visual acuities recovered well following treatment such as systemic corticosteroids, rituximab, and orbital surgery...The 2014 diagnostic criteria specify mucosa-associated lymphoid tissue (MALT) lymphoma as an important differential diagnosis for the relationship between IgG4-ROD and orbital lymphoma. The 2023 revision directs physicians' attention toward lymphomas other than MALT lymphoma, considering that the 2014 criteria might have placed too much emphasis on MALT lymphoma.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Journal:  A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients. (Pubmed Central) -  Aug 27, 2024   
    In this podcast, we discuss the evolving role of platinum-based chemotherapy in this disease setting in the context of EV-302 trial results and describe practical considerations in patients receiving first-line cisplatin- or carboplatin-based chemotherapy followed by avelumab maintenance therapy. This study provides evidence regarding the safety of ACE combination therapy in Japanese clinical practice using the DPC database, with results comparable to those reported in pivotal clinical trials.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Journal:  A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis. (Pubmed Central) -  Aug 27, 2024   
    Discontinuation of rituximab and avacopan resulted in improved liver function; no change in the Birmingham Vasculitis Activity Score during liver function test abnormalities was observed. Avacopan-associated abnormalities in liver function tests suggest that drug-induced liver injury may occur rapidly in children, and appropriate dosing strategies should be reconsidered.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Hypopyon Uveitis as a Manifestation of Primary Choroidal Lymphoma. (Pubmed Central) -  Aug 27, 2024   
    Primary choroidal lymphoma may occur with an atypical presentation, including hypopyon uveitis. Thus, familiarity with its clinical features is fundamental for an early recognition and correct management.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases:  Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure. (Pubmed Central) -  Aug 27, 2024   
    The experimental group consisted of 60 patients treated with the Sintilimab combined with Bevacizumab regimen...Patients aged ?60 years, male patients, and those in the experimental group showed better treatment responses in this study. By administering immune checkpoint inhibitors in combination with bevacizumab to patients with advanced colorectal cancer with MSS/pMMR disease for whom first-line treatment failed, not only did the patients' prognosis improve, but the adverse drug reactions were also safe and controllable.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Review, Journal:  Primary Hodgkin Lymphoma of the Breast: A Case Report and Literature Review Examining the Use of Different Chemotherapy Regimens. (Pubmed Central) -  Aug 27, 2024   
    Our case report is about a 48-year-old lady who was diagnosed with bilateral breast Hodgkin lymphoma following an excisional biopsy and was treated with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD)...There is scarce data on the classic Hodgkin lymphoma of the breast, and even with the wide use of first-line treatment using ABVD, the disease is still difficult to manage. Hence, patients with breast masses should be screened for classic HL of the breast, and larger studies are needed to establish specific treatment guidelines concerning HL of the breast to prevent relapse and other complications.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
    Journal, CAR T-Cell Therapy:  Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report. (Pubmed Central) -  Aug 27, 2024   
    Our patient presented with an extensive past medical history, including refractory B-ALL, and developed CRS and ICANS following treatment with blinatumomab CAR-T cell therapy. Early clinical detection of ICANS, monitoring using immune effector cell encephalopathy scores, following the appropriate protocol for ICANS grade, and adding anakinra (IL-1 receptor antagonist) were crucial steps in managing his condition.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Short segment myelitis as a dominant manifestation of cryptococcal infection: a case report. (Pubmed Central) -  Aug 27, 2024   
    We present short segment myelitis as a dominant manifestation caused by Cryptococcus neoformans in a patient with nephrotic syndrome under immunosuppressive therapy. This case report highlights Cryptococcus neoformans as a potential etiological factor for short segment myelitis in immunocompromised hosts.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead
    Journal:  Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma. (Pubmed Central) -  Aug 27, 2024   
    These changes may have been influenced by reimbursement policies and advances in clinical research. Based on these findings, prophylactic tocilizumab is not recommended to prevent CAR T-cell-related adverse events, and beneficial effects of prophylactic levetiracetam remain uncertain in patients with R/R LBCL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies. (Pubmed Central) -  Aug 27, 2024   
    Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded in hematologic malignancies...It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come.